Sarepta Therapeutics Inc
SRPT
Company Profile
Business description
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Contact
215 First Street
Suite 415
CambridgeMA02142
USAT: +1 617 274-4000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
1,314
Stocks News & Analysis
stocks
5 undervalued US shares that crushed earnings
These stocks are still cheap despite impressive earnings.
stocks
Undervalued ASX listed biotech refocuses
Fair value uneffected by suspended early-stage clinical trials.
stocks
We lift our fair value in wide moat ASX share
Signs of improvement in continued improvement in core business.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,629.20 | 74.80 | 0.87% |
| CAC 40 | 7,146.92 | 131.31 | -1.80% |
| DAX 40 | 18,865.45 | 323.74 | -1.69% |
| Dow JONES (US) | 43,389.60 | 55.39 | -0.13% |
| FTSE 100 | 8,058.94 | 50.38 | -0.62% |
| HKSE | 19,663.67 | 87.06 | 0.44% |
| NASDAQ | 18,791.81 | 111.69 | 0.60% |
| Nikkei 225 | 38,414.43 | 193.58 | 0.51% |
| NZX 50 Index | 12,816.32 | 51.67 | 0.40% |
| S&P 500 | 5,893.62 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,374.00 | 73.80 | 0.89% |
| SSE Composite Index | 3,346.01 | 22.16 | 0.67% |